Cargando…

How effective are ketamine or esketamine in treatment-resistant depression?

INTRODUCTION: Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veluri, N., Mansuri, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471430/ http://dx.doi.org/10.1192/j.eurpsy.2021.886

Ejemplares similares

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Does the crisis intervention team (CIT) training improve police officers’ knowledge, attitude, and mental health stigma?
por: Veluri, N., et al.
Publicado: (2021)

Is ketamine and lamotrigine interactions responsible for the sub-therapeutic effect of ketamine?
por: Adnan, M., et al.
Publicado: (2021)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
por: Correia-Melo, Fernanda S., et al.
Publicado: (2018)

Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression
por: Chan, Lai Fong, et al.
Publicado: (2022)

PS142. Ketamine is effective in an animal model of treatment resistant depression
por: Pereira, Vitor Silva, et al.
Publicado: (2016)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Adjunctive short- and long-term combination treatment of esketamine and VNS in difficult to treat depression (DTD)
por: Kavakbasi, E., et al.
Publicado: (2023)

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
por: Jollant, Fabrice, et al.
Publicado: (2023)

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine
por: Ma, Xiaofan, et al.
Publicado: (2023)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

Esketamine may be an ideal substitute for ketamine during cochlear function measurement
por: Li, Yufeng, et al.
Publicado: (2021)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial
por: Caliman-Fontes, Ana Teresa, et al.
Publicado: (2023)

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
por: Rognoni, Carla, et al.
Publicado: (2023)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
por: Salahudeen, Mohammed S, et al.
Publicado: (2020)

Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis
por: Zhan, Zhiqing, et al.
Publicado: (2021)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Gender differences in response and remission rates among patients receiving esketamine
por: Guterman, A. T., et al.
Publicado: (2023)

Clinical efficacy and tolerability of Esketamine: a case series
por: Passani, C., et al.
Publicado: (2022)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

How to deprescribe esketamine in resistant depression? A point of view after first clinical uses
por: Taillefer de Laportalière, T., et al.
Publicado: (2022)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
por: Degerlund Maldi, Kinza, et al.
Publicado: (2021)

S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis
por: Baune, B., et al.
Publicado: (2022)

Subcutaneous ketamine in the treatment of depression and suicide risk: case report.
por: Cigognini, M. A., et al.
Publicado: (2023)

The cognitive effects of esketamine: what do we know so far?
por: Barbosa, M., et al.
Publicado: (2022)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

PS103. Search for biomarkers for ketamine response from changes of cytokines in the patients with treatment resistant depression
por: Su, Tung-Ping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tnkf8l1laf938rbs8q9457nf3d